Turnover: 30 million EUR (2022)
Country: France
Founded in France in 1986, Laboratoires Sebbin manufactures and markets implants, expanders and other solutions for aesthetic and reconstructive surgery. Its production site, located in the Val d'Oise region of France, is controlled at every stage of production, and is characterized by quasi-artisanal methods.
Laboratoires Sebbin's strategy therefore draws on the Group's know-how and experience.
The group has 8 subsidiaries in Belgium, Germany, Spain, Austria, Switzerland, the UK, Argentina and Asia, and exports its products to some 60 countries in Europe, Latin America, North Africa/Middle East and Asia-Pacific.
It won the innovation prize at the annual congress organized by SOFCPRE in 2015 with its partner Crisalix for its innovation enabling patients to visualize their breasts in 3D after surgery.
News
The Sebbin group is investing in the Val d'Oise to double its size in the next five years. 04/02/2022
- Manufacturer of silicone breast implants for cosmetic surgery (70%) and reconstructive surgery (30%)
- 188 employees
- Objective: increase production by 50
- Sebbin generates 80% of its sales internationally through its own distribution subsidiaries, located mainly in England, Germany, Spain and the Netherlands
Financial Data
DUNS: 519665467
Legal Name: GROUPE SEBBIN
Address: 39 D'ACTIVITES LES QUATRE VENTS 39 PARC D ACTIVITES, 95650 BOISSY L'AILLERIE
Number of employees: Entre 100 et 199 salariés (2021)
Capital: 4 534 010 EUR
Financial Data:
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Turnover | 20 986 277 | 15 843 089 | 19 196 646 | 19 729 551 | 19 705 156 | 16 150 923 | 13 613 009 |
| Gross margin (€) | 15 280 049 | 12 103 079 | 14 571 240 | 15 620 464 | 13 073 256 | 13 050 231 | 11 077 686 |
| EBITDA (€) | 476 294 | -604 033 | 808 043 | 1 594 810 | -623 127 | 1 839 002 | 1 346 124 |
| Operating profit (€) | 425 452 | -945 210 | 470 580 | 1 472 963 | -1 939 270 | 696 529 | 620 143 |
| Net profit (€) | -957 516 | -1 523 849 | 103 039 | -2 529 801 | -8 468 092 | 106 367 | 305 874 |
| Turnover growth rate (%) | 32,5 | -17,5 | -2,7 | 0,1 | 22 | 18,6 | - |
| Ebitda margin rate (%) | 2,3 | -3,8 | 4,2 | 8,1 | -3,2 | 11,4 | 9,9 |
| Operating margin rate (%) | 2 | -6 | 2,5 | 7,5 | -9,8 | 4,3 | 4,6 |
| Working Capital (turnover days) | 70,3 | 136,9 | 96,3 | 108,8 | 103,3 | 301,3 | 316,1 |
| Working Capital requirements (turnover days) | 104,9 | 132,6 | 67,6 | 57,1 | 70,6 | 184,1 | 181,2 |
| Net margin (%) | -4,6 | -9,6 | 0,5 | -12,8 | -43 | 0,7 | 2,2 |
| Added value / Turnover (%) | 39,2 | 40,9 | 42,8 | 43,2 | 31,2 | 48,7 | 48,3 |
| Wages and social charges (€) | 7 335 306 | 6 721 273 | 6 985 502 | 6 299 612 | 6 312 187 | 5 725 373 | 4 922 458 |
| Salaries / Turnover (%) | 35 | 42,4 | 36,4 | 31,9 | 32 | 35,4 | 36,2 |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Directeur général | Jean-paul | Gerardin | 72 | |
| Commissaire aux comptes suppléant | Jean-pierre | Caro | 61 |
Studies mentioning this company
The aesthetic medicine market - France
Other companies mentioned:
- Allergan plc (Abbvie)
- Galderma
- Merz Pharmaceuticals
- La Roche-Posay
- Filorga Cosmétiques (Colgate Palmolive)
- Lierac (Laboratoire Native)
- Laboratoires Sebbin
- Arion
- Candela Medical
- Deleo
- Ipsen
- Clinique des Champs Elysées
- Lazeo
- Maison Lutetia
- Skincareagency
- Healshape
The aesthetic medicine market - Brazil
Other companies mentioned:
- Allergan plc (Abbvie)
- La Roche-Posay
- Laboratoires Sebbin
- Arion
The aesthetic medicine market - Portugal
Other companies mentioned:
- Allergan plc (Abbvie)
- La Roche-Posay
- Laboratoires Sebbin
- Arion
- Filorga Cosmétiques (Colgate Palmolive)